Hong Kong, Hong Kong, November 2nd, 2026, FinanceWire
Imagine a Hospital Where Critical Specimens No Longer Wait, Autonomous Robots and People Work as One, and Delivery Times Drop – a Pulse Equity Review
As hospitals look for ways to move critical supplies faster and more reliably, GIX Internet Ltd. (Nasdaq: GIXI; TASE: GIX) (“Gix” or the “Company”) is expanding the role of autonomous robots inside one of the world’s leading medical centers. Through its wholly owned subsidiary deliverz.ai, the Company is deploying robots through an AI-powered orchestration platform designed to coordinate different robot types and human teams. Recent announcements show its hospital robot operations moving beyond their initial use cases into additional critical logistics workflows.
Expanding Real-World Operations at Sheba Medical Center
On October 12, 2026, Gix announced that autonomous robots operated by deliverz.ai had begun transporting blood and bone marrow specimens at Sheba Medical Center, Israel’s largest hospital which has been ranked among the world’s top 10 hospitals by Newsweek, World’s Best Hospitals for 2026. The new workflows move bone marrow samples from the hematology department to the laboratory and donated blood from the donation center to the blood bank.
This builds on an existing commercial deployment focused on chemotherapy medication delivery that has been in operation since December 2025. According to Company data, average chemotherapy delivery time fell from approximately 40 minutes to approximately 14 minutes — a reduction of roughly 65%. As of October 2026, the platform had completed more than 9,000 autonomous missions across indoor and outdoor routes on the Sheba campus.
Sheba selected the platform under a public tender that permits deployment of up to 30 robots; three are currently in operation. The Company has stated that it plans further expansion to additional medication and diagnostic specimen routes. Michal Kaplansky, Sheba’s Head of Innovation for Human Experience, Operations and Logistics, has described autonomous logistics as critical operational infrastructure that frees staff to focus more on patient care.
Amir Nardimon, Chief Executive Officer of Gix, framed the expansion more broadly: “We are moving Physical AI from technology demonstrations into real-world, life-critical operations.” The Company emphasizes that a single orchestration platform can coordinate different robot types together with human teams and existing hospital systems (elevators, doors and access control).
The Platform and Business Model
deliverz.ai’s technology is designed as a robot-agnostic management and orchestration layer. It allocates tasks in real time based on location, priority, and availability, with an architecture designed to bring autonomous robots and human couriers under centralized management. Robot deliveries are already operating at Sheba Medical Center; orchestration of human transporters is a planned extension that has not yet been deployed. The Company offers the solution on both a software-as-a-service and robotics-as-a-service basis.
Gix has described hospital logistics as an initial commercial application of a broader architecture intended for other complex physical environments. In September 2026, the Company launched a new corporate website that articulates this vision of “one intelligent management layer for robots, people and autonomous systems.” The broader proposition is to give customers a common operational interface as they add robot vendors, workflows and autonomous systems. In that model, the hospital is an initial application of the orchestration platform, with expansion into other sectors still prospective.
Strategic Steps and Capital Markets Positioning
In September 2026, Gix made a $500,000 strategic investment in Ottonomy, a U.S. developer of Level-4 autonomous delivery robots, through a simple agreement for future equity. The companies also entered into a non-binding letter of intent that contemplates additional investments that could result in Gix acquiring a majority interest in Ottonomy. The stated rationale is to combine deliverz.ai’s orchestration software with Ottonomy’s navigation technology and robotic platforms. For Gix, the potential combination would add complementary robotics capabilities alongside its orchestration layer. Ownership of a robot developer need not limit the platform’s vendor independence: deliverz.ai’s strategy remains to support robots from multiple suppliers. There can be no assurance that definitive agreements will be signed or that any majority acquisition will be completed; any such transaction would be subject to definitive agreements and applicable approvals.
Separately, Gix holds an approximately 13% stake in Quantum X Labs. In late October 2026, the Company also announced it had initiated a process to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange, with the last trading day on TASE expected in January 2027. Shares will continue to trade on the Nasdaq Capital Market under the symbol GIXI. The board cited the objectives of potentially enhancing liquidity on Nasdaq and focusing investor and public-relations efforts on the U.S. capital markets.
Current Position and Growth Outlook
Gix’s current commercial footprint is still concentrated at Sheba Medical Center, which the Company presents as its operational foundation. The Company is introducing the platform to U.S. healthcare organizations, though no additional commercial deployments have been announced to date. The Company has indicated that the same management architecture could eventually apply to other sectors, but these opportunities remain prospective.
The combination of a live, multi-workflow hospital robot deployment, measurable time reductions, a robot-agnostic design, and selective strategic investments form the core of the narrative Gix is advancing. Whether this expands into a broader Physical AI platform will depend on the Company’s ability to replicate the Sheba results at additional sites and to execute on its stated technology and partnership roadmap.
Contact:
Pulse Equity
Office@Pulse-Equity.com
+852-95077298 (for media only)
Paid Promotional Disclosure
This article constitutes a paid promotional communication. GIX Internet Ltd. has engaged Pulse Equity, a brand/division of MR Solutions Limited, to provide investor awareness and promotional services, including the preparation and dissemination of this article, and has paid or for such services.
GIX Internet Ltd. reviewed and approved the content of this article but does not control how, when, or to whom the information is distributed by Pulse Equity.
This article is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of GIX Internet Ltd. Investing in GIX Internet Ltd.’s securities involves significant risks, and readers are encouraged to review GIX Internet Ltd.’s filings with the U.S. Securities and Exchange Commission available at www.sec.gov, and with the Israel Securities Authority available at www.magna.isa.gov.il, before making any investment decision.
Forward-Looking Statements
This article contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements in this article include statements regarding Gix’s and deliverz.ai’s plans and expectations regarding the expansion of autonomous robot deployments and logistics workflows at Sheba Medical Center; the potential deployment of additional robots, medication and diagnostic specimen routes and other use cases; the planned integration and orchestration of human transporters; the potential expansion and application of deliverz.ai’s technology and orchestration platform to additional healthcare organizations, customers, sites, sectors and physical environments, including in the United States; the Company’s ability to replicate the results of its deployment at Sheba Medical Center at additional sites; the Company’s technology, commercialization, partnership and growth strategies and roadmap; the potential benefits, capabilities and applications of deliverz.ai’s technology and business model; the Company’s investment in and relationship with Ottonomy, including potential additional investments, the negotiation and execution of definitive agreements, the possible acquisition of a majority interest in Ottonomy and the potential benefits of any such transaction or combination; the Company’s proposed voluntary delisting from the Tel Aviv Stock Exchange, including the expected timing thereof and the potential effects of the delisting on liquidity and the Company’s investor and public-relations efforts; and Gix’s potential development and expansion into a broader Physical AI platform. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including commercial adoption, implementation and integration challenges, financing requirements, competition, and the negotiation and completion of definitive agreements and applicable approvals. Readers should review the risks and uncertainties described in Gix Internet’s reports filed with the U.S. Securities and Exchange Commission (“SEC”) including, but not limited to, the risks detailed in the Company’s registration statement on Form 20-F (File No. 001-43362), as amended, as filed with the SEC on June 18, 2026, and in subsequent filings with the SEC, and the Israel Securities Authority. Forward-looking statements speak only as of the date they are made, and neither Gix Internet nor Pulse Equity undertakes any obligation to update them, except as required by law.
Pulse Equity Disclaimer
This article was produced by Pulse Equity, a brand / division of MR Solutions Limited
(Hong Kong), and is provided for general informational and promotional purposes only.
The content does not constitute investment advice, financial advice, medical advice, or a
recommendation to buy, sell, or hold any securities, nor does it constitute an offer or
solicitation in any jurisdiction.
Pulse Equity is not a registered broker-dealer, investment adviser, securities analyst, or
medical professional. The information presented is based on publicly available sources and statements believed to be reliable at the time of publication; however, Pulse Equity
makes no representations or warranties as to the accuracy or completeness of the
information and has not independently verified all data referenced.
This article is sponsored and compensated by the company discussed, which may create a conflict of interest.
Readers are encouraged to conduct their own independent research and consult qualified financial, legal, medical, or other professional advisers before making any investment or health-related decisions.
Forward-looking statements referenced in this article are subject to risks and uncertainties, and actual results may differ materially. Past performance is not indicative of future results.
For full disclosures, risk factors, and forward-looking statements, please visit:
https://pulse-equity.com/disclaimer/
Contact
Pulse Equity
Office@Pulse-Equity.com
+852-95077298 (for media only)
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Knox Market Research journalist was involved in the writing and production of this article.
